There have been studies on the relationship between glucagon like peptide-1 receptor agonists and vascular dementia.Therefore, the use of BRD4 degrading agents such as dBET1, the development of drugs that regulate the activity of the CCL2/CCR2 signaling pathway, the application of EDP targeted therapy, and glucagon like peptide 1 receptor agonists are all future research directions. The gene discussed is CCL2; the disease is vascular dementia.